PTPN21 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL16375396	1.00	1/20
SCHEMBL30366901	1.00	1/20
SCHEMBL16376118	0.92	1/20
SCHEMBL17669849	0.86	1/20
SCHEMBL16375397	0.83	1/20
SCHEMBL16376121	0.83	1/20
SCHEMBL18323176	0.79	1/20
SCHEMBL16375402	0.77	1/20
SCHEMBL30367054	0.77	1/20
SCHEMBL16376122	0.77	1/20
SCHEMBL18323109	0.77	1/20
SCHEMBL18323108	0.76	1/20
SCHEMBL16375399	0.75	1/20
SCHEMBL18323118	0.75	1/20
SCHEMBL30366941	0.75	1/20
SCHEMBL16376230	0.75	1/20
SCHEMBL16376231	0.73	1/20
SCHEMBL17669825	0.73	1/20
SCHEMBL16376232	0.72	1/20
SCHEMBL16375404	0.72	1/20

Clinical trials — most relevant to PTPN21 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance	PHASE4	UNKNOWN
Regulatory Lymphocytes in Patients Treated With Specific Immunotherapy	PHASE4	COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)	PHASE1/PHASE2	WITHDRAWN
Immunoregulatory Therapy for 2019-nCoV	PHASE2	UNKNOWN
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
Pembrolizumab (MK-3475) in MM Patients With Residual Disease	PHASE2	COMPLETED
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease	PHASE2	COMPLETED
A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma	PHASE2	UNKNOWN
SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme	PHASE2	UNKNOWN
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors	PHASE1	WITHDRAWN
A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors	PHASE1	RECRUITING
Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency	PHASE1	RECRUITING
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)	PHASE1	COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers	PHASE1	COMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease	nan	UNKNOWN
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.	nan	COMPLETED
Resistance to Immunotherapy in Gastric Cancer	nan	UNKNOWN
Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognitive Impairment	nan	NOT_YET_RECRUITING
Immunophenotypic Evaluation of CD305 and CD85d in B-Cell Lymphoid Neoplasms	nan	NOT_YET_RECRUITING
Effect of Non-surgical Periodontal Therapy on Gingival Crevicular Fluid Interleukin-21 Levels	nan	COMPLETED
Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4) Gene Single-nucleotide Polymorphism in Primary Immune Thrombocytopenic Purpura in Children	nan	NOT_YET_RECRUITING
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure	nan	UNKNOWN
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
Ibrutinib Adapted to Response in Patients With CLL	nan	UNKNOWN
Longitudinal Prognosis of Lymphoproliferative Manifestations in Primary Immunodeficiencies	nan	NOT_YET_RECRUITING
Expression of CD19 Complex in Lymphoproliferative Disorders	nan	UNKNOWN
The Effect of 0.1% Topical Ciclosporin A for 12-weeks on the Eye Surface Immune Cells in Dry Eyes	nan	RECRUITING
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia	nan	UNKNOWN
The Role of Autoantibodies Against G-protein Coupled Receptors in Obesity	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a PTPN21 binder may also engage these)

Protein	Name	Similarity
Q62136	—	1.000	Q62136 →
PTPN14	Tyrosine-protein phosphatase non-receptor type 14	1.000	landscape →
Q62728	—	1.000	Q62728 →
Q62130	—	0.996	Q62130 →
Q9Y2L6	—	0.991	Q9Y2L6 →
Q5M824	—	0.988	Q5M824 →
P59281	—	0.988	P59281 →
Q920B0	—	0.987	Q920B0 →
Q62925	—	0.987	Q62925 →
Q9HAU0	—	0.987	Q9HAU0 →
Q13905	—	0.987	Q13905 →
P34908	—	0.987	P34908 →
Q812E4	—	0.987	Q812E4 →
Q80W04	—	0.986	Q80W04 →
Q96NE9	—	0.985	Q96NE9 →
Q8C0V9	—	0.985	Q8C0V9 →
Q8TDW5	—	0.985	Q8TDW5 →
D4AB98	—	0.985	D4AB98 →
A5D794	—	0.985	A5D794 →
P78524	—	0.985	P78524 →
Q9C0H5	—	0.984	Q9C0H5 →
Q9H694	—	0.984	Q9H694 →
Q9WVB9	—	0.984	Q9WVB9 →
Q62415	—	0.984	Q62415 →
Q05AS8	—	0.984	Q05AS8 →
Q5R8Q4	—	0.984	Q5R8Q4 →
P34152	—	0.984	P34152 →
Q921C3	—	0.984	Q921C3 →
Q4V8Y7	—	0.984	Q4V8Y7 →
Q02225	—	0.984	Q02225 →